However, the fact that both HDAC and DNMT inhibitors have been identified in a recent high-throughput screening platform for polycystic kidney disease drug discovery [65] suggests that targeting epigenetic changes associated with ADPKD may be a way forward for new therapeutic development. The gene discussed is DNMT1; the disease is polycystic kidney disease.